{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-secretions/prescribing-information/dose-of-antimuscarinic/","result":{"pageContext":{"chapter":{"id":"1819f9d9-cb20-5283-9237-36370d8eaf04","slug":"dose-of-antimuscarinic","fullItemName":"Dose of antimuscarinic","depth":2,"htmlHeader":"<!-- begin field 1c3eebcb-033a-4d7e-acb6-d538cd2b2d6c --><h2>What dose of antimuscarinic should I use?</h2><!-- end field 1c3eebcb-033a-4d7e-acb6-d538cd2b2d6c -->","summary":"","htmlStringContent":"<!-- begin item 1e489c19-72fa-4cbc-a97e-e16ee4392c97 --><!-- begin field 0f71ad2a-b3cc-47c8-aca6-f005c97194c8 --><ul><li>Initially give a subcutaneous bolus injection of an antimuscarinic drug to treat noisy respiratory secretions, and if there is a positive response, continue administering the drug by subcutaneous infusion using a syringe driver.</li><li>Antimuscarinics can also be administered by repeated subcutaneous bolus injections at appropriate intervals, but use of regular injections is generally not practical or optimal for the patient. When given in this way, the dose and frequency of antimuscarinic drug administration varies according to the severity of respiratory secretions and patient response. They are usually given every 4 hours as required. </li><li>For antimuscarinic drug doses, see Table 2.</li></ul><p><strong>Table 2.</strong> Typical antimuscarinic drug doses for people with noisy respiratory tract secretions.</p><table><thead><tr><th colspan=\"1\">Drug</th><th colspan=\"1\">Initial bolus injection</th><th colspan=\"1\">Time interval to assess initial response</th><th colspan=\"1\">24-hour subcutaneous infusion dose</th></tr></thead><tbody><tr><td colspan=\"1\">Atropine sulfate</td><td colspan=\"1\">300 to 600 micrograms subcutaneously</td><td colspan=\"1\">30 to 60 minutes</td><td colspan=\"1\">1200 to 2400 micrograms</td></tr><tr><td colspan=\"1\">Hyoscine hydrobromide*</td><td colspan=\"1\">400 micrograms subcutaneously</td><td colspan=\"1\">20 to 30 minutes</td><td colspan=\"1\">800 to 2400 micrograms</td></tr><tr><td colspan=\"1\">Hyoscine butylbromide</td><td colspan=\"1\">20 mg subcutaneously</td><td colspan=\"1\">20 to 30 minutes</td><td colspan=\"1\">20 to 120 mg</td></tr><tr><td colspan=\"1\">Glycopyrronium bromide</td><td colspan=\"1\">200 to 400 micrograms subcutaneously</td><td colspan=\"1\">30 to 60 minutes</td><td colspan=\"1\">600 to 1200 micrograms†</td></tr><tr><td colspan=\"4\">* Hyoscine hydrobromide 1 mg can be administered every 72 hours via a transdermal patch (not commonly used for this indication in palliative care). The patch may be easier to use than subcutaneous administration, but it has a slow onset of action, and it is not well absorbed. In addition, the dose is insufficient for most people.† <sup>†</sup> Some experts suggest higher doses of glycopyrronium may be used in a subcutaneous infusion.</td></tr></tbody></table><p>These doses are based on expert opinion from palliative care resources [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">Bennett et al, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">Regnard, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">Twycross, 2014</a>], and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-secretions/references/\">BNF 72, 2016</a>].</p><ul><li>Note: none of these drugs are licensed for controlling respiratory secretions in palliative care, although they are used for this purpose in clinical practice.</li></ul><!-- end field 0f71ad2a-b3cc-47c8-aca6-f005c97194c8 --><!-- end item 1e489c19-72fa-4cbc-a97e-e16ee4392c97 -->","topic":{"id":"77f1b9af-1e60-5bb5-ae89-daa331210abe","topicId":"446cb057-c3b6-49c3-942c-3d8a40d02345","topicName":"Palliative care - secretions","slug":"palliative-care-secretions","lastRevised":"Last revised in October 2016","chapters":[{"id":"19f54d42-0888-50d9-a22b-cd4c095d346e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"72433d6d-9301-5ca8-b910-6a552d6fce9c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"025bff54-f52a-54fb-b384-42f6b7abfb71","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"09dcf8ce-9483-5303-b1b2-68579072438f","slug":"changes","fullItemName":"Changes"},{"id":"fffc9f9e-45d1-50c5-be5f-b864988702ac","slug":"update","fullItemName":"Update"}]},{"id":"f0f7d1a1-4f58-53b4-a82a-1cee73e34be5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5cf603f8-c6db-5f9a-8053-8078d5ca7704","slug":"goals","fullItemName":"Goals"},{"id":"d5a9411c-4efe-55f8-a100-b669fa635333","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a870297-6340-5e00-91f5-76791ba8bc25","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"acfb93e5-0ab7-5b5e-abea-421e101ee036","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"76d1d9b7-098a-51c5-a8c8-ed432c562045","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"82517897-fd42-5e8b-9c87-986916cd1a05","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4296b2d-b51d-58ce-8564-c1f97f3e17d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7f6c0c77-0b74-5509-99a0-d46ccbb5df6a","slug":"definition","fullItemName":"Definition"},{"id":"a280c209-3fa8-5a6e-8cf1-77ecdb0c548f","slug":"why-do-secretions-accumulate","fullItemName":"Why do secretions accumulate"},{"id":"fcc81d76-7a24-5377-9a9c-871e7849434d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"6b5cc8f0-3cab-5d14-900a-459f40793235","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"aeac360c-7bd9-5b2d-a7f0-979347e4a423","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b6e50011-ccf0-5fd1-b5ba-a11dab328604","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"6f40bc41-9977-54ec-b25f-77e34d1c3cac","fullItemName":"Management","slug":"management","subChapters":[{"id":"1365445e-f6e4-583d-84ac-dfa2d7ec2981","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"f01d488f-b942-5c1f-839b-84f60cb644a3","slug":"noisy-respiratory-secretions-at-the-end-of-life","fullItemName":"Scenario: Noisy respiratory secretions at the end of life"}]},{"id":"8d463ab9-510c-50ff-b9e2-2a5202e4693e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"24d654c1-72b5-5691-b5ab-2b633207259e","slug":"which-antimuscarinic-to-prescribe","fullItemName":"Which antimuscarinic to prescribe"},{"id":"1819f9d9-cb20-5283-9237-36370d8eaf04","slug":"dose-of-antimuscarinic","fullItemName":"Dose of antimuscarinic"},{"id":"0e997e9e-35ef-5150-9b22-44631bbe9875","slug":"adverse-effects-of-antimuscarinics","fullItemName":"Adverse effects of antimuscarinics"},{"id":"c4ecff94-72a7-5298-9eff-aa0f014bd0d2","slug":"administering-drugs-via-syringe-driver","fullItemName":"Administering drugs via syringe driver"}]},{"id":"fc7ec3a1-6164-5fce-ae68-ea76a7e7ed95","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"f0bd35d1-28aa-5304-bbae-6437a5cff4f8","slug":"antimuscarinics-for-respiratory-secretions","fullItemName":"Antimuscarinics for respiratory secretions"}]},{"id":"13aa02e3-ed7e-5603-b3cf-c8c77f16c1ad","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9720e3b4-46d0-5fc7-a0db-be67e6db6bfa","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92414bd0-2c9f-584a-badf-10b45f202fc3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"42fc232e-bba3-513f-a5d9-15378200e570","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"68c17f61-0db1-544c-a0b5-b14bb9ce5c5c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bf6037b2-67c3-5d11-ae91-c606813ad76d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"741bbef8-7d2e-53e4-ae09-0cb22ef8d617","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8d463ab9-510c-50ff-b9e2-2a5202e4693e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}